A detailed history of Bfsg, LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Bfsg, LLC holds 300 shares of JANX stock, worth $14,628. This represents 0.0% of its overall portfolio holdings.

Number of Shares
300
Previous 400 25.0%
Holding current value
$14,628
Previous $16,000 18.75%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

SELL
$35.29 - $50.26 $3,529 - $5,026
-100 Reduced 25.0%
300 $13,000
Q2 2024

Jul 29, 2024

BUY
$35.12 - $64.78 $14,047 - $25,912
400 New
400 $16,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.03B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Bfsg, LLC Portfolio

Follow Bfsg, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bfsg, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bfsg, LLC with notifications on news.